Skip to main content
. 2014 Jul 8;124(9):1426–1433. doi: 10.1182/blood-2014-03-560557

Figure 1.

Figure 1

Kaplan-Meier survival estimates according to randomization. (A) Median EFS times for patients who received LDAC (n = 45) and LDAC + volasertib (n = 42) were 2.3 and 5.6 months, respectively (HR, 0.57; 95% CI, 0.35-0.92; P = .021); 1-year EFS was 14.6% and 29.0%. (B) Median RFS times were 10.0 and 18.5 months for LDAC (n = 6) and LDAC + volasertib (n = 13), respectively. (C) Median OS times for patients who received LDAC (n = 45) and LDAC + volasertib (n = 42) were 5.2 and 8.0 months, respectively (HR, 0.63; 95% CI, 0.40-1.00; P = .047); 1-year OS was 22.2% and 36.8%. Database snapshot November 7, 2013. NR, not reported.